[HTML][HTML] Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator
L Romero-Pinel, L Bau, E Matas, I León, R Juvany… - Plos one, 2022 - journals.plos.org
Background The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.
L Romero-Pinel, L Bau, E Matas, I León, R Juvany… - Plos one, 2022 - europepmc.org
Background The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
Cost associated with a relapse-free patient in multiple sclerosis: a real-world health indicator
L Romero Pinel, L Bau, E Matas Martín… - PLoS One, 2022, vol …, 2022 - diposit.ub.edu
Background: The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
[HTML][HTML] Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator
L Romero-Pinel, L Bau, E Matas, I León, R Juvany… - PLoS ONE, 2022 - ncbi.nlm.nih.gov
Background The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.
L Romero-Pinel, L Bau, E Matas, I León… - PLoS …, 2022 - search.ebscohost.com
Background: The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator
L Romero-Pinel, L Bau, E Matas, I León… - PloS …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator
L Romero-Pinel, L Bau, E Matas, I León… - PLoS …, 2022 - ui.adsabs.harvard.edu
Background The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.
L Romero-Pinel, L Bau, E Matas, I León, R Juvany… - Plos one, 2022 - europepmc.org
Background The efficacy and safety of disease-modifying therapies (DMTs) in multiple
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …
sclerosis (MS) are well known; however, owing to their high costs, determining real-world …